Business
Net Asset Value calculation to 31 March 2016
Net Asset Value calculation to 31 March 2016.
About this update from Agronomics Limited
[{"type":"text","content":"\n \nRNS Number : 7471W Port Erin Biopharma Investments Ltd 28 April 2016 \n\n29 April 2016\nPort Erin Biopharma Investments Limited\n(the \"Company\")\n \nNet Asset Value calculation to 31 March 2016\n \nJim Mellon, Chairman, commented: -\n\"The Net Asset Value (\"NAV\") calculation for the Company as at closing on 31 March 2016 was 10.21 pence per share, including un-invested cash of £10,713. The portfolio is valued under IFRS at bid price.\nNet Assets stand at £2.4 million including Investments of £2.38 million. This quarter's NAV represents a decrease of 5.37% from the previous valuation of 10.79 pence per share, which included un-invested cash of £24,011. No additional management fee is due to Shellbay Investments Limited.\"\n\n\n\n\n\n\n\n\n\n\nUnaudited to 31 March 2016 (£)\n\n\n\n\nFixed Assets\n\n\n\n\n\n\n\n\n\n\n\n\n\nInvestments\n\n\n2,375,370\n\n\n\n\nCurrent Assets\n\n\n\n\n\n\n\n\n\n\n\n\n\nSundry Debtors\n\n\n34,522\n\n\n\n\n\n\n\nUninvested cash\n\n\n10,713\n\n\n\n\nCurrent Liabilities\n\n\n\n\n\n\n\n\n\n\n\n\n\nCreditors: amounts due\n\n\n(51,777)\n\n\n\n\n\n\n\n\n\n\n2,368,828\n\n\n\n\nCapital and Reserves\n\n\n\n\n\n\n\n\n\n\n\n\n\nShare Capital\n\n\n23\n\n\n\n\n\n\n\nShare Premium\n\n\n1,890,142\n\n\n\n\n\n\n\nReserves\n\n\n478,663\n\n\n\n\n\n\n\n\n\n\n2,368,828\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nShares in Issue\n\n\n\n\n\n23,195,558\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNet Asset Value per share\n\n\n\n\n\n10.21 pence\n\n\n\n\n \n\n\n \nPortfolio Details\n \n\n\n\n\nInvestments as at 31 March 2016\n\n\nValue\n\n\n% of Total Portfolio\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMagna Biopharma Income Fund\n\n\n£1,093,235\n\n\n46.0%\n\n\n\n\n\n\n\nRegent Pacific Group\n\n\n£600,945\n\n\n25.3%\n\n\n\n\n\n\n\nSummit Corporation\n\n\n£251,293\n\n\n10.6%\n\n\n\n\n\n\n\nOther quoted holdings\n\n\n£96,082\n\n\n4.0%\n\n\n\n\n\n\n\nOther unquoted holdings\n\n\n£333,815\n\n\n14.1%\n\n\n\n\n\n\n\nTotal\n\n\n£2,375,370\n\n\n100.0%\n\n\n\n\n\n\n\n\n\n\n\n\n \nFor further information, please contact:\n \n\n\n\n\nPort Erin Biopharma\nInvestments Limited\n\n\nNorthland Capital Partners \nLimited\n\n\nPeterhouse Capital \nLimited\n\n\n\n\nThe Company\n\n\nNomad and Joint Broker\n\n\nBroker\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nDenham Eke\n(+44) (0) 1624 639396\n\n\nMatthew Johnson/David Hignell\n(+44) (...